Investigating the Pharmacokinetics of Subcutaneous Injections With 1 mg/mL, 3 mg/mL, and 10 mg/mL Semaglutide Strengths and the Absolute Bioavailability of Semaglutide

NCT02231684 · Completed

Last updated 2026-05-28

This clinical trial is studying how different doses of semaglutide, given as injections under the skin, are absorbed and processed in the body by people with diabetes and healthy volunteers.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 42 people

Who can join Ages 18–55 · all sexes Healthy volunteers accepted.

Timeline Started 2014-09 · est. completion 2015-01

Where 1 site · Germany

What this study is testing ClinicalTrials.gov NCT02231684 ↗

Description as written by the study sponsor.

This trial is conducted in Europe. The aim of this trial is to investigate the pharmacokinetics (the exposure of the trial drug in the body) of subcutaneous injections of three different strengths of semaglutide and the absolute bioavailability of semaglutide.

Treatments tested

semaglutide Drug

Semaglutide administered subcutaneously (s.c. under the skin) in two out of three different strengths (1mg/mL, 3mg/mL and 10 mg/mL).
semaglutide Drug

Semaglutide administered subcutaneously (s.c. under the skin) in two out of three different strengths (1mg/mL, 3mg/mL and 10 mg/mL) or intravenously (i.v.) (1mg/mL).

Main thing measured	Area under the semaglutide plasma concentration curve
Sponsor	Novo Nordisk A/S
Conditions studied	Diabetes, Healthy
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02231684 ↗